These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26673713)

  • 21. CIViCpy: A Python Software Development and Analysis Toolkit for the CIViC Knowledgebase.
    Wagner AH; Kiwala S; Coffman AC; McMichael JF; Cotto KC; Mooney TB; Barnell EK; Krysiak K; Danos AM; Walker J; Griffith OL; Griffith M
    JCO Clin Cancer Inform; 2020 Mar; 4():245-253. PubMed ID: 32191543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.
    Rhodes DR; Kalyana-Sundaram S; Mahavisno V; Varambally R; Yu J; Briggs BB; Barrette TR; Anstet MJ; Kincead-Beal C; Kulkarni P; Varambally S; Ghosh D; Chinnaiyan AM
    Neoplasia; 2007 Feb; 9(2):166-80. PubMed ID: 17356713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects.
    Simonds NI; Khoury MJ; Schully SD; Armstrong K; Cohn WF; Fenstermacher DA; Ginsburg GS; Goddard KA; Knaus WA; Lyman GH; Ramsey SD; Xu J; Freedman AN
    J Natl Cancer Inst; 2013 Jul; 105(13):929-36. PubMed ID: 23661804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical trial landscape in oncology and connectivity of somatic mutational profiles to targeted therapies.
    Patterson SE; Liu R; Statz CM; Durkin D; Lakshminarayana A; Mockus SM
    Hum Genomics; 2016 Jan; 10():4. PubMed ID: 26772741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tri©DB: an integrated platform of knowledgebase and reporting system for cancer precision medicine.
    Jiang W; Wang PY; Zhou Q; Lin QT; Yao Y; Huang X; Tan X; Yang S; Ye W; Yang Y; Bao YJ
    J Transl Med; 2023 Dec; 21(1):885. PubMed ID: 38057859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy.
    Amoedo ND; Obre E; Rossignol R
    Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):674-685. PubMed ID: 28213330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets.
    Guo J; Liu H; Zheng J
    Nucleic Acids Res; 2016 Jan; 44(D1):D1011-7. PubMed ID: 26516187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting drug resistance related to ABC transporters using unsupervised Consensus Self-Organizing Maps.
    Estrada-Tejedor R; Ecker GF
    Sci Rep; 2018 May; 8(1):6803. PubMed ID: 29717183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Introduction: Cancer Gene Networks.
    Clarke R
    Methods Mol Biol; 2017; 1513():1-9. PubMed ID: 27807826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MEDICI: Mining Essentiality Data to Identify Critical Interactions for Cancer Drug Target Discovery and Development.
    Harati S; Cooper LA; Moran JD; Giuste FO; Du Y; Ivanov AA; Johns MA; Khuri FR; Fu H; Moreno CS
    PLoS One; 2017; 12(1):e0170339. PubMed ID: 28118365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Reversal of drug resistance and prediction of the response to cytostatics. Experimental drug therapy for tumors has clinical potential].
    Larsson R; Nygren P; Bergh J
    Lakartidningen; 1991 Dec; 88(51-52):4441-4. PubMed ID: 1774991
    [No Abstract]   [Full Text] [Related]  

  • 32. Systematic, network-based characterization of therapeutic target inhibitors.
    Shen Y; Alvarez MJ; Bisikirska B; Lachmann A; Realubit R; Pampou S; Coku J; Karan C; Califano A
    PLoS Comput Biol; 2017 Oct; 13(10):e1005599. PubMed ID: 29023443
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Druggable cancer secretome: neoplasm-associated traits.
    Narayanan R
    Cancer Genomics Proteomics; 2015; 12(3):119-31. PubMed ID: 25977171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular genomic features associated with in vitro response of the NCI-60 cancer cell line panel to natural products.
    Krushkal J; Negi S; Yee LM; Evans JR; Grkovic T; Palmisano A; Fang J; Sankaran H; McShane LM; Zhao Y; O'Keefe BR
    Mol Oncol; 2021 Feb; 15(2):381-406. PubMed ID: 33169510
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New therapeutic targets in cancer: the epigenetic connection.
    Herranz M; Esteller M
    Clin Transl Oncol; 2006 Apr; 8(4):242-9. PubMed ID: 16648099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cancer in silico drug discovery: a systems biology tool for identifying candidate drugs to target specific molecular tumor subtypes.
    San Lucas FA; Fowler J; Chang K; Kopetz S; Vilar E; Scheet P
    Mol Cancer Ther; 2014 Dec; 13(12):3230-40. PubMed ID: 25349306
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A tool for discovering drug sensitivity and gene expression associations in cancer cells.
    Qin Y; Conley AP; Grimm EA; Roszik J
    PLoS One; 2017; 12(4):e0176763. PubMed ID: 28453553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CancerDR: cancer drug resistance database.
    Kumar R; Chaudhary K; Gupta S; Singh H; Kumar S; Gautam A; Kapoor P; Raghava GP
    Sci Rep; 2013; 3():1445. PubMed ID: 23486013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Key drivers of biomedical innovation in cancer drug discovery.
    Huber MA; Kraut N
    EMBO Mol Med; 2015 Jan; 7(1):12-6. PubMed ID: 25422355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Clinical Kinase Index: A Method to Prioritize Understudied Kinases as Drug Targets for the Treatment of Cancer.
    Essegian D; Khurana R; Stathias V; Schürer SC
    Cell Rep Med; 2020 Oct; 1(7):100128. PubMed ID: 33205077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.